Lynch syndrome patients in Germany rarely use aspirin for cancer prevention

A study published in The Lancet Gastroenterology & Hepatology reveals a significant gap between scientific evidence and clinical practice regarding cancer prevention for individuals with Lynch syndrome in Germany. The LYNX study, which surveyed 539 participants, found that only 6.9% of those with the hereditary condition used aspirin (acetylsalicylic acid) specifically for cancer prevention, despite evidence that it can reduce colorectal cancer risk.

While participants showed high awareness of screening recommendations and regular colonoscopies, the adoption of preventative medication remains low. Researchers noted that while previous studies like CAPP2 utilized a 600 mg daily dose, more recent findings from the CaPP3 study suggest that a lower dose of 100 mg may offer similar preventive benefits with fewer side effects, such as bleeding complications.

Dr. Robert Hüneburg of University Hospital Bonn emphasized the need for improved, personalized communication between clinicians and patients to address this disconnection and evaluate the risks and advantages of preventative aspirin use.